Suvretta Capital Management’s EyePoint Pharmaceuticals EYPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $64M | Hold |
6,804,091
| – | – | 1.93% | 14 |
|
|
2025
Q1 | $36.9M | Buy |
6,804,091
+21,000
| +0.3% | +$114K | 1.37% | 22 |
|
|
2024
Q4 | $50.5M | Buy |
6,783,091
+1,607,268
| +31% | +$12M | 1.72% | 15 |
|
|
2024
Q3 | $41.4M | Hold |
5,175,823
| – | – | 1.32% | 28 |
|
|
2024
Q2 | $45M | Buy |
5,175,823
+1,411,935
| +38% | +$12.3M | 1.65% | 19 |
|
|
2024
Q1 | $77.8M | Sell |
3,763,888
-292,959
| -7% | -$6.06M | 2.89% | 7 |
|
|
2023
Q4 | $93.8M | Buy |
4,056,847
+564,700
| +16% | +$13.1M | 4.24% | 6 |
|
|
2023
Q3 | $27.9M | Buy |
3,492,147
+68,250
| +2% | +$545K | 1.51% | 22 |
|
|
2023
Q2 | $29.8M | Buy |
3,423,897
+29,000
| +0.9% | +$252K | 1.59% | 20 |
|
|
2023
Q1 | $9.98M | Buy |
3,394,897
+47,000
| +1% | +$138K | 0.42% | 50 |
|
|
2022
Q4 | $11.7M | Buy |
3,347,897
+114,300
| +4% | +$400K | 0.49% | 49 |
|
|
2022
Q3 | $25.6M | Buy |
3,233,597
+265,390
| +9% | +$2.1M | 1.06% | 38 |
|
|
2022
Q2 | $23.4M | Buy |
2,968,207
+58,800
| +2% | +$463K | 0.89% | 39 |
|
|
2022
Q1 | $35.3M | Buy |
2,909,407
+389,707
| +15% | +$4.73M | 1.08% | 34 |
|
|
2021
Q4 | $30.8M | Buy |
2,519,700
+815,111
| +48% | +$9.98M | 0.6% | 42 |
|
|
2021
Q3 | $17.8M | Buy |
1,704,589
+326,257
| +24% | +$3.4M | 0.3% | 48 |
|
|
2021
Q2 | $12.4M | Buy |
1,378,332
+197,132
| +17% | +$1.77M | 0.19% | 75 |
|
|
2021
Q1 | $12M | Buy |
+1,181,200
| New | +$12M | 0.18% | 68 |
|